April 16, 2024 News by Margarida Maia, PhD MS patients may be at higher risk of stroke: Review study The risk of having a stroke, that is, a blockage in blood flow to the brain that can cause lasting damage, is about 2.5 times higher in people with multiple sclerosis (MS) than the general population, a review of multiple studies finds. The researchers called for further studies to…
November 15, 2021 News by Mary Chapman Wearable ‘Neural Sleeve’ Counters Foot Drop, Aids Mobility in Study People in a Neural SleeveĀ gaitĀ study were reported to show an “average improvement” of 143% in foot drop, a common symptom ofĀ multiple sclerosis (MS) and other conditions that hinder mobility, its developer, Cionic, reports. The wearable ābionicā device ā which analyzes, predicts,…
June 13, 2019 News by Marisa Wexler, MS Elevated Blood Pressure May Predict Brain Bleeding in RRMS Patients Treated with Lemtrada, Study Suggests New research suggests that rising blood pressure might be predictive of intracranial hemorrhage ā bleeding in the brain, a serious and sometimes fatal condition ā in people with multiple sclerosis (MS) who are receiving treatment with Lemtrada (alemtuzumab). The study, titled “Intracerebral haemorrhage during…
December 3, 2018 News by Ana Pena PhD Lemtrada’s Use Carries Rare But Serious Risk of Stroke and Artery Tears, FDA Warns The U.S. Food and Drug Administration (FDA)Ā has issued a safety alert, warning about a rare but life-threatening risk of stroke and artery rupture in patients with relapsing forms of multiple sclerosis (MS)Ā being treated with Lemtrada (alemtuzumab). Since Lemtrada’s approval in 2014 to treat relapsing MS, 13…
October 1, 2018 News by Ana Pena PhD MS Patients Using Rebif Not at Higher Stroke Risk, Even Over Long-term, Study Reports Multiple sclerosis patients usingĀ RebifĀ (interferon beta-1a) are not at an increased risk of a stroke, even if remaining on this therapy for more than two years,Ā a study analyzing safety data from more than a dozen clinical trials and post-marketing surveillance shows. The…
May 16, 2017 News by Alice MelĆ£o, MSc RRMS Patients on Beta-Interferon Therapy Have Increased Risk of Stroke, Study Finds A large-scale study revealed potential adverse reactions to beta-interferon (IFN-Ī²) therapy, one of the most common treatments used for relapsing-remitting multiple sclerosis (RRMS). According to the study published in the journal Neurology, patients have an increased risk of stroke, migraine, depression, and of developing abnormalities in the blood. In…
April 24, 2017 News by Janet Stewart, MSc Glove with Sensors Measures Spasticity More Accurately than Physicians A Ā multidisciplinary team at the University of California at San Diego has come up with a computerized glove used as a sensor to measure spasticity, or stiffness, in the limbs of patients with multiple sclerosis, cerebral palsy, and stroke. The system is more accurate than physiciansā assessments of spasticity…
October 31, 2014 News by Patricia Inacio, PhD Neuroprotective Qualities of Masitinib Drug in Stroke Encouraging For MS Indication An encouraging experimental drug that is being developed for Multiple Sclerosis continues to show promise in being able to offer neuroprotective benefits — an effect that could slow and eventually cure MS.Ā Masitinib,Ā which is being developed by AB Science forĀ numerous neurological indications, including Alzheimer’s disease, progressive multiple sclerosis, and amyotrophic…